The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but placing funds in companies heavily reliant on unbranded versions presents a uncertain picture. Although early profits were substantial, the cessation of patents and the rise of discounted alternatives have eroded market share. Therefore, a thorough evaluation